Latest news : Gamida Cell Ltd.

27/05/25	Gamida Cell Ltd. cancelled the acquisition of bluebird bio, Inc. from BlackRock, Inc., The Vanguard Group, Inc. and others.	CI
22/07/24	HOOKIPA Pharma Appoints Malte Peters CEO, Terry Coelho CFO	MT
18/06/24	Gamida Cell Names Rory Nealon as Chief Financial Officer	CI
18/06/24	Gamida Cell Names Sheila Frame as Chief Commercial Officer	CI
18/06/24	Gamida Cell Ltd. Names Joe Wiley as Chief Executive Officer	CI
18/06/24	Gamida Cell Ltd. announced that it has received $30 million in funding from Highbridge Capital Management, LLC	CI
24/05/24	Gamida Cell Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
10/04/24	Gamida Cell Ltd.(NasdaqGM:GMDA) dropped from S&P Global BMI Index	CI
05/04/24	Gamida Cell Ltd.(OTCPK:GMDA.Q) dropped from NASDAQ Composite Index	CI
28/03/24	Wall Street Set to Open Flat in Thursday Trading; Q4 US GDP Revised Up, Weekly Jobless Claims Fall	MT
28/03/24	Top Premarket Decliners	MT
27/03/24	Top Midday Decliners	MT
27/03/24	Wall Street Set to Open Higher Wednesday as Investors Eye End-of-Week Economic, Inflation Data	MT

More news

Analysts' recommendations : Gamida Cell Ltd.

29/01/24	JMP Securities Downgrades Gamida Cell to Market Perform From Market Outperform	MT
15/11/23	Piper Sandler Adjusts Gamida Cell's Price Target to $2 From $5, Maintains Overweight Rating	MT
15/11/23	HC Wainwright Adjusts Price Target on Gamida Cell to $5 From $11, Keeps Buy Rating	MT
19/05/23	JMP Securities Adjusts Price Target on Gamida Cell to $6 From $8, Keeps Market Outperform Rating	MT
16/05/23	Oppenheimer Adjusts Gamida Cell Price Target to $6 From $8, Maintains Outperform Rating	MT

More recommendations

Press Releases : Gamida Cell Ltd.

27/03/24	Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management	AQ
27/03/24	Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update	AQ
22/03/24	Gamida Cell to Report Fourth Quarter and Full-Year 2023 Financial Results	AQ
23/02/24	Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®	AQ
29/01/24	Gamida Cell Actively Pursuing Strategic Alternatives	AQ

More press releases

Managers and Directors : Gamida Cell Ltd.

Manager	Title	Age	Since
Joe Wiley CEO	Chief Executive Officer	55	-
Heayoung Shin CTO	Chief Tech/Sci/R&D Officer	-	01/06/2021
Rory Nealon COO	Chief Operating Officer	59	24/05/2024

Director	Title	Age	Since
Joe Wiley CHM	Chairman	55	-
George Hampton BRD	Director/Board Member	56	01/04/2019

More insiders

Gamida Cell Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The Company is leveraging its nicotinamide (NAM)-based cell expansion technology toto expand multiple cell types including stem cells and natural killer (NK) cells while maintaining their original phenotype and potency. The Company's clinical pipeline products include: Omidubicel dedicated to hematologic malignancies and severe aplastic anemia; GDA-201 dedicated for treatment of non-Hodgkin Lymphoma; GDA-301, GDA-401, GDA-501 dedicated to treatment of solid tumors, GDA-601 dedicated to multiple myeloma.

Employees

147

Sector

Biotechnology & Medical Research

More about the company

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - OTC Markets 20:54:51 24/05/2024 +04			5-day change	1st Jan Change
0.0170 ^USD	+2.41%		-.--%	-

Market Cap	2.62M 2.26M 2.12M 1.94M 3.64M 249M 3.66M 25.17M 9.78M 126M 9.83M 9.62M 419M	P/E 2022	-1.04x	P/E 2023	-0.72x
Enterprise Value	39.01M 33.65M 31.65M 28.86M 54.2M 3.7B 54.59M 375M 146M 1.88B 146M 143M 6.25B	EV / Sales 2022	-	EV / Sales 2023	51,081,230x
Free-Float	89.41%	Yield 2022 *	-	Yield 2023	-

3 years	0.01	1.26
5 years	0.01	4.76
10 years	0.01	15.41

Date	Insider	Type	Main position	Quantity	% Market Cap.
31/01/24	Ronit Simantov	Free	Chief Technology Officer	480,319	0.3621%
31/01/24	Ivan Borrello	Free	Director	200,000	0.1508%
31/01/24	Kenneth Moch	Free	Director	200,000	0.1508%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GAMIDA CELL LTD.	+2.41%	-.--%	-.--%	-98.56%	2.62M
WUXI APPTEC CO., LTD.	-0.25%	-0.92%	+49.47%	+89.45%	68.13B
ARGENX SE	+1.21%	+2.55%	+46.72%	+90.66%	63.6B
WUXI BIOLOGICS (CAYMAN) INC.	+1.31%	+1.81%	+49.04%	+12.07%	25.57B
INSMED INCORPORATED	-0.25%	-1.99%	-10.72%	+455.09%	26.6B
BIONTECH SE	+0.33%	-9.64%	+1.95%	-15.70%	25.52B
PHARMAESSENTIA CORPORATION	-6.09%	-11.19%	+224.80%	+351.08%	18.23B
GENMAB A/S	+1.18%	+1.66%	+35.20%	-18.67%	19.69B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.49%	-6.35%	+7.84%	+540.26%	15.16B
EXELIXIS, INC.	+4.12%	+4.29%	+52.03%	+154.09%	13.54B
Average	+0.25%	-3.09%	+45.63%	+155.98%	27.6B
Weighted average by Cap.	+0.15%	-2.87%	+47.00%	+145.57%

Gamida Cell Ltd. Stock

Stocks

GMDA

IL0011552663

Biotechnology & Medical Research

Valuation : Gamida Cell Ltd.

Latest news : Gamida Cell Ltd.

Analysts' recommendations : Gamida Cell Ltd.

Press Releases : Gamida Cell Ltd.

Quotes and Performance

Price Extremes

Managers and Directors : Gamida Cell Ltd.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

	2022	2023
Net sales	-	1.78 1.54 1.45 1.32 2.48 169.37 2.5 17.15 6.66 86.11 6.7 6.55 285.75
Net income	-79.38M -68.47M -64.41M -58.73M -110M -7.54B -111M -763M -296M -3.83B -298M -292M -12.71B	-63M -54.34M -51.12M -46.61M -87.53M -5.98B -88.16M -606M -235M -3.04B -237M -231M -10.09B
Net Debt	39.31M 33.91M 31.9M 29.08M 54.62M 3.73B 55.01M 378M 147M 1.9B 148M 144M 6.3B	36.39M 31.39M 29.53M 26.92M 50.56M 3.45B 50.92M 350M 136M 1.76B 137M 134M 5.83B